-
Wall Street Reacts To Spark Therapeutics' $850K Genetic Blindness Treatment
Wednesday, January 3, 2018 - 12:59pm | 589Read More...The first gene therapy treatment ever approved in the U.S. comes with a steep price tag. On Wednesday, Spark Therapeutics Inc (NASDAQ: ONCE) announced it will charge $425,000 per eye for one-time treatments of a rare genetic retinal disease that causes blindness. The new therapy could be a huge...
-
Chimerix: Piper's 'Post-Blow-Up' Play
Tuesday, January 19, 2016 - 11:26am | 236Read More...Piper Jaffray issued a company note on Chimerix Inc (NASDAQ: CMRX) after a disappointing clinical trial, calling the company a "post-blow-up opportunity." Piper Jaffray rates Chimerix as Overweight and increased their price target from $11 to $18. Analysts Joshua Schimmer, Steven...
